| Abstract: |
To the Editor: Several pieces of data are needed to interpret the conclusion of Fisher et al. (April 8 issue)1 that CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) “remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin's lymphoma.” First, how many centers contributed patients, and how many patients did the average center assign to each regimen? The study included 233 patients treated with ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, and etoposide followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue), and the complete-response rate was 56 percent, a level 30 percent lower than that reported by the National... © 1993, Massachusetts Medical Society. All rights reserved. |
